- Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease | One-time treatment with LentiGlobin resulted in sustained production of HbAT87Q in most red cells, leading to reduced hemolysis and complete resolution of severe vaso-occlusive events. https://www.nejm.org/doi/full/10.1056/NEJMoa2117175 2 comments science
Linking pages
- The pharma industry from Paul Janssen to today: why drugs got harder to develop and what we can do about it | Alex’s blog https://atelfo.github.io/2023/12/23/biopharma-from-janssen-to-today.html 5 comments
- A Future History of Biomedical Progress | Markov Bio https://markov.bio/biomedical-progress/ 0 comments
Linked pages
- CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia | NEJM https://www.nejm.org/doi/full/10.1056/nejmoa2031054 461 comments
- Gene Therapy in a Patient with Sickle Cell Disease | NEJM http://www.nejm.org/doi/full/10.1056/nejmoa1609677?query=featured_home 8 comments
- VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19 | NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2208822 0 comments
Related searches:
Search whole site: site:www.nejm.org
Search title: Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease | NEJM
See how to search.